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A microscopic mass balance approach has shown that the initial saturation (Is), absorption 
number (An), dose number (Do), and dissolution number (Dn) are four fundamental di- 
mensionless parameters that can be used to estimate the fraction dose absorbed (~ of suspen- 
sions of poorly soluble drugs in humans. The dissolution number of a drug increases with de- 
creasing its particle size. The effect of micronization on F for suspensions was investigated in 
terms of Dn. About 90% of maximal Fcan be achieved at Dn-~2. Increasing the solubility of 
a drug results in better oral absorption through increasing Dn and decreasing Do. The frac- 
tions dose absorbed of digoxin, griseofulvin, and benoxaprofen agree with predicted F values 
using estimated parameters. Drugs with low Do and low Dn can be more completely ab- 
sorbed by reducing particle size, while absorption of drugs with high Do and low Dn is lim- 
ited by solubility and requires higher solubility to enhance the fraction dose absorbed in ad- 
dition to micronization. Solubility at the physiological pH should be used for the estimation of 
the fraction dose absorbed. 
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INTRODUCTION 
It has been shown that the absorption of several 
poorly soluble drugs administered in suspension for- 
mulations is dissolution-rate limited (Abdou, 1989). 
According to the dissolution equation derived from 
the film theory, dissolution rate is directly pro- 
portional to the surface area, the solubility of a com- 
pound, and its concentration gradient across the dif- 
fusion layer. In general, micronization of a com- 
pound enhances the dissolution rate due to the in- 
crease in surface area available to the dissolving 
medium. The dissolution rate can also be increased 
by increasing the solubility, which is usually ac- 
complished by pH effect, salt formulation, solu- 
bilization by surface active agents, change in crystal 
form, complexation, or by a sufficient reduction in 
particle size (Leeson and Carstensen, 1974). In- 
creasing the dissolution rate usually results in more ra- 
pid and complete absorption. Poor aqueous solubility 
may cause a slow dissolution rate. Recently the im- 
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portance of the dose to solubility ratio on the extent 
of absorption has been discussed (Dressman, 1989; 
Sinko et al., 1991). 
There are instances in which particle size reduction 
fails to increase the absorption rate of a drug (Gibaldi, 
1984). For drugs with aqueous solubilities below 0.1 
mg/ml, micronization may not be enough to get com- 
plete oral absorption depending on the dose. Mi- 
cronization sometimes dramatically increases the ten- 
dency of a drug powder to aggregate, which may 
lead to a decrease in effective surface area. The ef- 
fective surface area of hydrophobic drug particles 
may be increased by the addition of a wetting agent 
to the formulation. 
A microscopic mass balance approach has been 
employed for prediction the bioavailability of suspen- 
sions (Oh et aL, 1993) and the drug-drug interaction 
(Oh and Amidon, 1995). It was shown by Oh et al. 
(1993) that the fraction dose absorbed (F) from 
suspensions of poorly soluble compounds is govern- 
ed by four fundamental dimensionless parameters: in- 
itial saturation (Is), absorption number (An), dose 
number (Do), and dissolution number (Dn). The ef- 
fects of particle size and solubility on F from suspen- 
sions can be explained by Dn and Do. The ob- 
427 
428 D.M. Oh, R.L. Curl, C.S. Yong and G.L. Amidon 
jectives of this report are to demonstrate the effects of 
micronization and solubilization on the fraction dose 
absorbed from suspensions of poorly soluble drugs 
and to determine when micronization can sig- 
nificantly increase F. Furthermore the pH effect on 
solubility for weak electrolytes will be discussed in 
order to estimate F. 
dr* 
dz* 
dC* 
Fraction dose absorbed of suspensions 
To predict the fraction dose absorbed from suspen- 
sions of poorly soluble compounds, a microscopic 
mass balance approach has been developed (Oh et 
al., 1993). A physical tube model with a plug flow 
containing particles is employed. The length of the in- 
testine is / with radius R and initial radius of particles 
is r0. Mass balances in both solid phase and solution 
phase were considered to get the set of differential e- 
quations: 
= _ Dn 1-C* 
3 r* (I) 
dz* 
where, 
- Dn. Do-r* (1 -C*)-2 An.C* 
An = P~ff (3) 
Q/(~ R L) 
Do-  M~176 (4) 
C, 
Dn = (D/ro) C, (4 ~ r~)/(4~ r~ p) 
Q/(~ R 2 L) 
Pe~ is the effective wall permeabilty, Q is the volu- 
metric flow rate iP the intestine, and Mo is the dose 
taken with water volume of Vc, For dimensionless 
parameters, z*=z/L, r*=rff'r0, and C*=C/C,, where z 
is the axial coordinate down the intestine and rp and 
Cz are the radius of particles and the luminal con- 
centration at z, respectively. C,, D, and p are the solu- 
bility, diffusivity, and density of the compound, 
respectively. An is the absorption number, which is 
the ratio of radial absorption rate to axial convection 
rate, Do is the dose number, which is the ratio of 
dose concentration to solubility of a compound, and 
Dn is the dissolution number, which is the ratio of 
residence time in the intestine to dissolution time 
from initial particles. 
To estimate the extent of drug absorption, it is as- 
sumed that the dose taken is the sum of the initially 
dissolved amount is solution and the remaining 
amount in solid at the beginning of the intestine. The 
initial saturatiion, Is, is defined to be: 
Is = CL(0)/Cs (6) 
where C,(0) is the luminal concentration at the be- 
ginning of the intestine. Is is the dimensionless inlet 
concentration in solution. For poorly soluble drugs, Is 
is close to zero so that C*=0 and r*=l at the be- 
ginning of the intestine (z*= 0). 
It is assumed that the difference between mass in 
and mass out of the intestine is equal to be the mass 
absorbed at steady state. From the mass balance in 
the intestine, the fraction dose absorbed (k9 is: 
C*(1 ) 
F = 1-{r*(1)} ~- Do (7) 
where r*(1) and C*(1) are the dimensionless radius of 
particles and the dimensionless concentration at the 
end of the intestine. The values of r*(1) and C'(1) can 
be calculated from Eqs. (1) and (2) by a numerical 
method (Oh et al., 1993). 
Simulation 
Differential equations were solved by the Runge- 
Kutta-Merson method. Simulation was performed with 
a personal computer using a NDP Fortran-386 com- 
piler (Microway, Inc., Kingston, MA). The absorption 
number (An) of griseofulvin is about 7 and was cal- 
culated from single-pass perfusion data in rats 
(Poelma, 1989). The value of An for other drugs in as- 
sumed to be 7, based on the fact that they are non- 
polar of moderate moleular weight (Sinko et al., 
1991). The conclusion would be essentially the same 
for any An greater than about 1 (Oh et al., 1993). 
The initial saturation was assumed to be 0 (r*=l and 
C*=0 at z*=0) because most poorly soluble drugs 
have very slow dissolution rates. The volume flow 
rate was assumed to be 1 ml/min, and the luminal 
volume was taken to be 250 ml if it was not given in 
the literature. Dose number and dissolution number 
were calculated by Eqs. (4) and (5), respectively. 
RESULTS AND DISCUSSION 
It has been shown in the previous paper (Oh et al., 
1993) that there are four fundamental dimensionless 
parameters to estimate the fraction dose absorbed (f) 
of suspensions: initial saturation (Is), absorption numb- 
er (An), dose number (Do), and dissolution number 
(Dn). Fig. 1 shows a three dimensional graph and 
contour for the fraction dose absorbed in the plot of 
dose number versus dissolution number at An=5 and 
Is=O. It is clearly demonstrated that F is dependent 
on both Do and Dn at a fixed An. In addition to /30 
and Dn, An can vary F (Oh et aL, 1993). In general, 
the fraction dose absorbed may be limited by low An, 
low Dn, or high /30, or by any combination thereof. 
For example, a drug with high An, low Do and high 
Dn is well absorbed. As shown in Fig. 2, an increase 
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Fig. 1. Three dimensional graph and contour of the fraction 
dose absorbed (F) in the polt of dose number (Do) versus 
dissolution number (Dn) at An=5 and Is=O. 
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Fig. 2. Plot of fraction dose absorbed (F) versus dissolution 
number (Dn) at several different absorption numbers (An=l, 
5,7). Bar(I) indicates 90% of maximal F which can be ob- 
tained at no dissolution limitation. Values of parameters 
used for calculations: s Is=O. 
in An results in higher F. However, absorption cannot 
be complete only by increasing An and Dn if Do is 
too high. Fig. 2 shows that Fis about 0.15 at s 
even when An is 7. Fig. 3 shows a plot of the frac- 
tion dose absorbed versus dissolution number at sev- 
eral dose numbers. At higher Dn, the reduction in F 
is significant with increasing Do. If a drug has a low 
An and/or high Do, its chemical structure needs to be 
Aa~=7 
Do- I  
1.0 Do -- 10 
0.8 
0.6 
F 
0.4 
Do ~ 50 
0.2 Do 100 
0.0 
0.01 0.10 1.00 10.00 
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Fig. 3. Plot of fraction dose absorbed (F) versus dissolution 
number (Dn) at several different dose numbers (Do=l, 10, 
50, 100). Bar(I) indicates 90% of maximal F which can be 
obtained at no dissolution limitation. Values of parameters 
used for calculations: An=-7, /9=0. 
modified to obtain a better wall permeability, higher 
solubility and higher potency. Taking more water is 
also favorable to F through decreasing Do. 
Another way to increase the fraction dose absorbed 
of a drug is to increase Dn. The dissolution number is 
the ratio of residence time in the intestine to the dis- 
solution time of the particles, and is a function of 
solubility, diffusivity, density, initial particle radius of 
a drug, and volumetric flow rate in the intestine. A 
typical way to increase Dn in pharmaceutics is to 
reduce the particle size, since Dn is inversely pro- 
portional to the square of the initial radius of the par- 
ticles. However F reaches a plateau as Dn increases 
(Fig. 2). 
Ten percent (0.1"Fmax) and 90% (0.9" F,~a~) of max- 
imal F (obtained at no dissolution limitation; Dn--~ ~) 
are shown in Fig. 4, illustrating that 0.9. F,~ can be 
achieved in the range of 1 to 3 of Dn. Bars in Fig. 2 
and Fig. 3 also indicate 90% of maximal F. This 
points out that the micronization does not increase F 
significantly if Dn is larger than about 2. In this case 
F is limited by other variables such as Do and we ref- 
er to this as solubility (or dose number) limited ab- 
sorption. A compound that falls in the region 
between 0.1. F,~x and 0.9. F,,~x is most sensitive to mi- 
cronization. 
Digoxin and griseofulvin were chosen because they 
have similar solubilities but quite different doses. Solu- 
bilities of digoxin and griseofulvin are 0.024 mg/ml 
and 0.015 mg/ml, respectively. The dose number of 
digoxin ranges from 0.1 to 0.5 (dose of 0.25 to 0.5 
mg), while that of griseofulvin ranges 67 to 267 (dose 
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Fig. 4. Ten percent (0.1 9 F,,~) and 90% (0.9. Fm~) of max- 
imal F (at no dissolution limitation; Dn --, oo) in the plot of 
Do versus Dn for An of 1,5, and 10. Dotted lines represent 
the dose numbers at Dn --~ oo. 
of 250 to 1000 mg). Fig. 5 shows the fraction dose ab- 
sorbed of digoxin at various Dn. Predicted values are 
calculated using /3o=0.1, An=7, and Is=0, and re- 
ported data were taken from the literature (Jounela et 
al., 1975; Johnson et aL, 1978). Good agreement 
between reported and predicted fractions dose ab- 
sorbed is observed. A Dn of 1.3 (particle radius of 26 
~m) results in 90% absorption. Jounela et al. (1975) 
reported that the bioavailability of digoxin with mean 
120 
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Fig. 5. Fraction dose absorbed (F) of digoxin. Predicted 
values are shown by a solid line. Values of parameters used 
for calculations:/3o=0.1, An=7, Is=O. Human dat were tak- 
en from Jounela et al. (1975) and Johnson et aL (1978). 
9 : Johnson et al. (1978), 9 : Jounela et al. (1978) 
particle radii of 3.5 or 6.5 ~m was 78 to 97%, while 
that with larger particle size (51 l~m) was only 39%. 
It was also demonstrated that absorption from a for- 
mulation of particle radius of 45 to 53 I~m was reduc- 
ed about 43% of that of micronized digoxin (5 l~m of 
radius) (Johnson et aL, 1978). The present analysis 
suggests that complete oral absorption of digoxin may 
be expected if particle radius is smaller than 26 gm. 
There are however some conflicting reports in the 
literature. Shaw and Carless (1974) found in human 
patients that the bioavailability of digoxin with a par- 
ticle radius of 11 ~m was about 46% compared to 
that when given in solution, and that reduction of 
mean particle radius from 11 Ilm to 1.85 l~m resulted 
in 31% increase in mean digoxin plasma level. There 
is a significant shift to the right on the plot of F versus 
Dn, indicating that more micronization is required to 
get the same F in patients. The reason for this dis- 
crepancy is not known. It may be from shifts on Dn 
and An. However the comparison of bioavailability 
data from patients with those of healthy volunteers 
cannot be possible without any attempt to normalize 
the human data. 
In the case of griseofulvin, Do is very high so that 
the Do limitation of F may be expected even if Dn is 
large. Fig. 6 shows the fraction dose absorbed of 
griseofulvin with predicted lines for 13o=67 and Do= 
267. Reported F values were scattered over the range 
estimated, partly due to its absorption variability 
(Atkinson et al., 1962; Khalafalla et al., 1980; 
Terhaag et al., 1985). Each point in Fig. 6 has various 
Do ranging 67 to 267, even if they are from the same 
report. Micronization may play a role to increase F, 
but particle size in most formulations of griseofulvin 
is already small enough so that Dn is much larger 
Effect of Micronization on the Absorption of Suspensions 431 
than 2. Therefore reducing the particle size does not 
increase F very much, without reducing Do. This 
may be a reason that a meaningful correlation 
between dissolution rate and extent of griseofulvin ab- 
sorption was not observed (Khalafalla et aL, 1980). It 
was suggested from Fig. 6 that the variability in 
bioavailability might result primarily from high Do. 
To increase F of griseofulvin, Do must be reduced by 
enhancing its solubility. It may, in part, expain the 
better absorption of griseofulvin in the fed state. Phy- 
siolgical surface active agents, like bile salts and lyso- 
lecithin, probably facilitate the dissolution and ab- 
sorption of poorly water-soluble drugs in the small in- 
testin (Miyazaki et al., 1980). 
50 
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t 
Do= 67 
. . . . . . . . . . . . . . . . . . . . . . . . . . .  J . . . . . . .  J . . . . . . .  J 
0.1 1 10 100 I000 10000 
Dn 
Fig. 6. Fraction dose absorbed (F) of griseofulvin. Predicted 
values are shown by solid lines. Values of parametrers used 
for calcuations: s and 267, An=7, Is=0, Human data 
were taken from Atkinson et al. (1962), Khalafalla et al. 
(1980), and Terhaag et al. (1985). 
o: Atkinson et al. (1962)-tablets, @: Atkinson et al. (1962)- 
capsules, 4: Khalaflla eta/. (1980), 9 : Terhasg eta/. (1985) 
To improve bioavailability of suspensions in prac- 
tical situations, the physicochemical properties of in- 
terest are the radius of particles and solubility, in ad- 
dition to the dose taken. Contours of the fraction 
dose absorbed in the plot of solubility and the radius 
of particles for two different initial dose con- 
centrations (2 mg/ml or 0.1 mg/ml) are shown in Fig. 
7. It shows the dependency of F on the dose con- 
centration, the solubility, and the radius of the par- 
ticles. For drugs with a high dose concentration and 
low solubility (as with griseofulvin), the effect of mi- 
cronization may not be significant (Fig. 7(A)). On the 
other hand, drugs with low dose concentration and 
low solubility (such as digoxin) may be completely 
absorbed by reducing their particle size (Fig. 7(B)). 
Ridolfo et al. (1979) reported that solubilities of be- 
noxaprofen, an antiinflammatory drug, were dramat- 
ically changed with increasing pH. Higher solubility 
at higher pH decreases Do and increases Dn, result- 
ing in a greater fraction dose absorbed. The simu- 
lations in Figs. 1 to 4 don't apply to benoxaprofen, 
since Is value is expected to vary as a function of pH. 
Changing solubility makes Is to increase at higher pH 
values. Fig. 8 shows the fraction dose absorbed of be- 
noxaprofen at various pH values with two different Is 
values (Is=0 and 1). It shows estimated data of F at 
two different particle sizes (9.25 pm and 305 p.m) of 
benoxaprofen and the reported values of F in the 
literature (Wolen et aL, 1979). As expected, estimated 
F increases with increasing pH, pointing out that the 
physiological pH should be used to estimate F for 
weak electrolytes. In case of benoxaprofen the proper 
pH is 6 to 7 to estimate F in humans (Fig. 8). Several 
estimated F values of benoxaprofen at pH 7.0 were 
shown in Table I, which is in good agreement with re- 
ported F values (Ridolfo et al., 1979; Wolen et al., 
1979; Nash et al., 1980). It should be pointed out 
that Is=l rather than Is=O may be appropriate at the 
(A) Mo/Vo = 2 ms/mL 
A 
B 1.ooo 
im 
v 0.100 
~l 0.010 
v , , ,q  
0 
I 0.000 . . . . . . . . . . . . . . . . . . . . .  F r  I0.000 
1.000 
0.100 
0.010 
0.001 i . . . . . . . . . . . . . . . . . . . . . . . .  0.001 
1 1o 10o 1000 
Rad ius  o f  Par t i c les  (pm)  
(B) Mo/Vo - 0.I ms/mL 
. . . . . . . .  i . . . . . . . .  i . . . . .  
10 100 1000 
Rad ius  o f  Par t ic les  (pro)  
Fig. 7. Contours of fraction dose absorbed (/9 in the plot of solubility and radius of particles for Mo/Vo=2 mg/mL (A) or 0.1 
mg/mL (B). Values of parameters used for calculations: An=7, ls=O. 
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Fig. 8. Fraction dose absorbed (F) of benoxaprofen at vari- 
ous pH values. Dose is 200 mg and radii of particles are 9. 
25 Ia.m (A) or 305 IJ.m (B). The fractions dose absorbed are 
estimated using Is=O or 1 and An=7. The closed bars 
represent he reported values in the literature (Wolen et al., 
1979). 
" : Wolen eta/. (1979), m: Estimated F (Is=l), u: Estimated 
F (Is=0) 
Table I. Estimated and reported fractions dose absorbed (/9 
of benoxaprofen ~
Do Dn An Estimated F(%) Reported Reference 
/s = 0 Is = 1 F (%) 
2.7 0.07 7.0 6.7 42.3 60 b 
2.7 6.72 7.0 100.0 100.0 100 b 
7.7 52.40 7.0 100.0 100.0 98 c 
11.6 52.40 7.0 99.6 99.6 95 c 
4.8 88.18 7.0 100.0 100.0 96 d 
4.8 0.08 7.0 7.2 27.0 41 d 
19.3 0.08 7.0 6.7 11.3 22 d 
adensity=1000 mg/ml, solubility=0.207 mg/ml (at pH=7.0) 
bfrom Ridolfo et al. (1979) 
Cfrom Nash et al. (1980) 
dfrom Wolen et al. (1979). 
pH where a drug has higher solubility. The cal- 
culated F was somewhat underestimated compared to 
the reported F, suggesting a partial role of the in- 
trinsic bile salts. In addition to the effect of bile salts, 
pH variation down the intestine may change the wall 
permeability of the compound. The physical model 
may be refined by introducting the effect of sur- 
factants and ionization on Dn and Do. 
In summary, the fraction dose absorbed of suspen- 
sions can be estimated from a dissolution model with 
parameters; Is, An, Do, and Dn. The dose, the radius 
of particles, and the solubility at the physiological pH 
are needed for estimation of F. About 90% of max- 
imal F can be achieved at Dn-~2. Drugs with low 
Do and low Dn can be completely absorbed by 
reducing their particle sizes, while the absorption of 
drugs with high Do and low Dn is solubility (dose 
number) limited and requires a higher solubility, in 
addition to micronization, to enhance the fraction 
dose absorbed. 
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